Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) major shareholder Michael Rapp purchased 25,745 shares of the business’s stock in a transaction on Monday, October 23rd. The shares were acquired at an average price of $9.94 per share, for a total transaction of $255,905.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Michael Rapp also recently made the following trade(s):

  • On Thursday, October 19th, Michael Rapp purchased 44,255 shares of Zynerba Pharmaceuticals stock. The shares were acquired at an average price of $9.59 per share, for a total transaction of $424,405.45.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) traded up 1.75% during mid-day trading on Monday, hitting $9.90. 483,291 shares of the company were exchanged. The stock’s market cap is $131.24 million. Zynerba Pharmaceuticals, Inc. has a 12 month low of $5.42 and a 12 month high of $25.95. The firm has a 50 day moving average price of $8.19 and a 200 day moving average price of $8.19.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Tuesday, August 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Analysts anticipate that Zynerba Pharmaceuticals, Inc. will post ($2.42) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/zynerba-pharmaceuticals-inc-zyne-major-shareholder-michael-rapp-buys-25745-shares.html.

Several hedge funds and other institutional investors have recently modified their holdings of ZYNE. JPMorgan Chase & Co. increased its holdings in shares of Zynerba Pharmaceuticals by 65,190.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 326,450 shares of the company’s stock valued at $5,539,000 after acquiring an additional 325,950 shares during the last quarter. Citigroup Inc. increased its holdings in shares of Zynerba Pharmaceuticals by 13,501.1% in the 2nd quarter. Citigroup Inc. now owns 221,698 shares of the company’s stock valued at $3,762,000 after acquiring an additional 220,068 shares during the last quarter. State Street Corp bought a new stake in shares of Zynerba Pharmaceuticals in the 2nd quarter valued at approximately $2,698,000. Vanguard Group Inc. increased its holdings in shares of Zynerba Pharmaceuticals by 53.9% in the 1st quarter. Vanguard Group Inc. now owns 425,811 shares of the company’s stock valued at $8,559,000 after acquiring an additional 149,094 shares during the last quarter. Finally, Pennsylvania Trust Co bought a new stake in shares of Zynerba Pharmaceuticals in the 2nd quarter valued at approximately $2,366,000. Institutional investors and hedge funds own 34.32% of the company’s stock.

A number of brokerages have issued reports on ZYNE. Cantor Fitzgerald reiterated a “hold” rating and set a $4.00 price target on shares of Zynerba Pharmaceuticals in a research note on Thursday, September 28th. Jefferies Group LLC lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the stock from $12.00 to $7.00 in a research note on Tuesday, August 15th. HC Wainwright set a $7.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, August 15th. Maxim Group lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Finally, Oppenheimer Holdings, Inc. lowered shares of Zynerba Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $14.22.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.